Dicerna Pharmaceuticals Announces Fourth Quarter And Full Year 2013 Financial And Operational Results
Published: Mar 28, 2014
Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leader in the development of RNAi-based therapeutics, today provided a corporate update and announced operational and financial results for the fourth quarter and full year ended December 31, 2013.
“In 2013, Dicerna achieved very substantial financial and operational objectives in our mission to build an innovative drug development company based on the powerful Dicer Substrate RNA interference technology,” commented Douglas M. Fambrough, PhD, Dicerna’s President and CEO.
Help employers find you! Check out all the jobs and post your resume.